Although considerable progress has been made in the diagnosis and treatment of congenital heart disease‐associated pulmonary heart hypertension (CHD‐PAH), the clinical prognosis and overall survival of patients with CHD‐PAH remain… Click to show full abstract
Although considerable progress has been made in the diagnosis and treatment of congenital heart disease‐associated pulmonary heart hypertension (CHD‐PAH), the clinical prognosis and overall survival of patients with CHD‐PAH remain poor. Therefore, the molecular pathogenesis of CHD‐PAH requires further investigation. The intermediate filament protein synemin (SYN) is reported to modulate phenotypic alterations and varicose vein development, but there is little understanding of its exact functions in CHD‐PAH.
               
Click one of the above tabs to view related content.